Buminate (Baxalta US Inc.)


Welcome to the PulseAid listing for the Buminate drug offered from Baxalta US Inc.. This Human Serum Albumin [EPC],Increased Intravascular Volume [PE],Increased Oncotic Pressure [PE],Osmotic Activity [MoA],Serum Albumin [Chemical/Ingredient] pharmaceutical is classified as a PLASMA DERIVATIVE. Below, you can view the details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same PLASMA DERIVATIVE drug type category.

LABELER NAME / MANUFACTURER: Baxalta US Inc.
NON-PROPRIETARY NAME: Albumin Human
SUBSTANCE NAME: ALBUMIN HUMAN
TYPE: PLASMA DERIVATIVE
PHARMA CLASS: Human Serum Albumin [EPC],Increased Intravascular Volume [PE],Increased Oncotic Pressure [PE],Osmotic Activity [MoA],Serum Albumin [Chemical/Ingredient]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION, SOLUTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 1954-03-17
END MARKETING DATE: 0000-00-00


Buminate PLASMA DERIVATIVE Details:

Item DescriptionBuminate from Baxalta US Inc.
LABELER NAME: Baxalta US Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 0.25(g/mL)
START MARKETING DATE: 1954-03-17
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0944-0490_2d4ce1ae-31d8-495e-855b-e1a587631e67
PRODUCT NDC: 0944-0490
APPLICATION NUMBER: BLA101452

Other ALBUMIN HUMAN Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Baxalta US Inc.Buminate
CSL Behring AGAlbuRx
GRIFOLS USA, LLCALBUTEIN
KEDRION BIOPHARMA, INC.Albuked